Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Ferrand

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Human Gene Therapy|June 19, 2008
Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistanceEmad Bennour, Christophe Ferrand, Jean-Paul Rémy-Martin, et al.
Current Research in Translational Medicine|February 11, 2023
CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humansClémentine Nicod, Mathieu Neto da Rocha, Walid Warda, et al.
Cancers|December 9, 2020
EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung CarcinomasCamille Lachat, Diane Bruyère, Amandine Etcheverry, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|November 5, 2011
CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometryFrançoise Solly, Fanny Angelot, Richard Garand, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 29, 2016
IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent MannerRomain Loyon, Emilie Picard, Olivier Mauvais, et al.
Oncoimmunology|July 29, 2016
Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patientsCaroline Laheurte, Jeanne Galaine, Laurent Beziaud, et al.
Experimental Hematology & Oncology|March 4, 2016
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignanciesClémentine Gamonet, Elodie Bole-Richard, Aurélia Delherme, et al.
Experimental Hematology & Oncology|April 16, 2016
Erratum to: New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignanciesClémentine Gamonet, Elodie Bole-Richard, Aurélia Delherme, et al.
Blood|July 16, 2011
Successful mobilization and engraftment of PBSCs derived from donor cord blood cells after a previous allogeneic RIC single unrelated cord blood transplantationFabrice Larosa, Eric Deconinck, Philippe Helias, et al.
Bulletin Du Cancer|November 28, 2017
[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Ibrahim Yakoub-Agha, Christophe Ferrand, Yves Chalandon, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Human Gene Therapy|June 19, 2008
Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistanceEmad Bennour, Christophe Ferrand, Jean-Paul Rémy-Martin, et al.
Current Research in Translational Medicine|February 11, 2023
CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humansClémentine Nicod, Mathieu Neto da Rocha, Walid Warda, et al.
Cancers|December 9, 2020
EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung CarcinomasCamille Lachat, Diane Bruyère, Amandine Etcheverry, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|November 5, 2011
CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometryFrançoise Solly, Fanny Angelot, Richard Garand, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 29, 2016
IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent MannerRomain Loyon, Emilie Picard, Olivier Mauvais, et al.
Oncoimmunology|July 29, 2016
Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patientsCaroline Laheurte, Jeanne Galaine, Laurent Beziaud, et al.
Experimental Hematology & Oncology|March 4, 2016
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignanciesClémentine Gamonet, Elodie Bole-Richard, Aurélia Delherme, et al.
Experimental Hematology & Oncology|April 16, 2016
Erratum to: New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignanciesClémentine Gamonet, Elodie Bole-Richard, Aurélia Delherme, et al.
Blood|July 16, 2011
Successful mobilization and engraftment of PBSCs derived from donor cord blood cells after a previous allogeneic RIC single unrelated cord blood transplantationFabrice Larosa, Eric Deconinck, Philippe Helias, et al.
Bulletin Du Cancer|November 28, 2017
[Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T-cell therapy (CAR T-cells): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Ibrahim Yakoub-Agha, Christophe Ferrand, Yves Chalandon, et al.
Pageof 11